CR20180465A - Composiciones y métodos para tratar artritis reumatoide - Google Patents

Composiciones y métodos para tratar artritis reumatoide

Info

Publication number
CR20180465A
CR20180465A CR20180465A CR20180465A CR20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A
Authority
CR
Costa Rica
Prior art keywords
treat
compositions
methods
reumatoid arthritis
arthritis
Prior art date
Application number
CR20180465A
Other languages
English (en)
Inventor
Alexander; Boddy
Neil; Graham
Adelsberg Janet; Van
Hoogstraten Hubert; Van
Yong; Lin
Deborah; Bauer
Janie; Parrino
Rahul; Patel
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of CR20180465A publication Critical patent/CR20180465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de un anticuerpo anti-receptor de IL6 en monoterapia para tratar la artritis reumatoide y para mejorar la función física y la calidad de vida de un sujeto que padece artritis reumatoide.
CR20180465A 2016-03-07 2017-03-07 Composiciones y métodos para tratar artritis reumatoide CR20180465A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CR20180465A true CR20180465A (es) 2019-03-04

Family

ID=58387910

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180465A CR20180465A (es) 2016-03-07 2017-03-07 Composiciones y métodos para tratar artritis reumatoide

Country Status (18)

Country Link
US (1) US20190100585A1 (es)
EP (1) EP3426295A1 (es)
JP (2) JP7166925B2 (es)
KR (3) KR20260049875A (es)
CN (1) CN109069642A (es)
AU (2) AU2017229364A1 (es)
BR (1) BR112018067851A2 (es)
CA (1) CA3016880A1 (es)
CL (1) CL2018002559A1 (es)
CR (1) CR20180465A (es)
EA (1) EA201892005A1 (es)
IL (2) IL261515B2 (es)
MX (2) MX2018010815A (es)
PH (1) PH12018501894A1 (es)
SG (2) SG10202012182YA (es)
TN (1) TN2018000312A1 (es)
TW (3) TW202419103A (es)
WO (1) WO2017155990A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
SG11202101674QA (en) * 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) * 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
MX377190B (es) * 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Also Published As

Publication number Publication date
CA3016880A1 (en) 2017-09-14
TWI747885B (zh) 2021-12-01
TW201808993A (zh) 2018-03-16
SG10202012182YA (en) 2021-01-28
JP2023011711A (ja) 2023-01-24
JP7745529B2 (ja) 2025-09-29
SG11201807614SA (en) 2018-10-30
TW202419103A (zh) 2024-05-16
MX2023014841A (es) 2024-01-15
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
TWI819435B (zh) 2023-10-21
US20190100585A1 (en) 2019-04-04
KR20260049875A (ko) 2026-04-14
TW202239767A (zh) 2022-10-16
JP7166925B2 (ja) 2022-11-08
CN109069642A (zh) 2018-12-21
EA201892005A1 (ru) 2019-02-28
EP3426295A1 (en) 2019-01-16
IL261515A (en) 2018-10-31
IL308539A (en) 2024-01-01
TN2018000312A1 (en) 2020-01-16
MX2018010815A (es) 2019-01-10
NZ746988A (en) 2023-10-27
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
JP2019507775A (ja) 2019-03-22
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
KR20180114955A (ko) 2018-10-19
AU2024203011A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
MX2018010815A (es) Composiciones y metodos para tratar artritis reumatoide.
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
SA517381664B1 (ar) أجسام مضادة تستهدف مستقبل مقترن ببروتين وطرق استخدامها g
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
MX2020012064A (es) Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
MX2023005881A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
AR081750A1 (es) Anticuerpos anti-cd40
MX2016012188A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
CO2021011352A2 (es) Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopática